English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT02972840 /

ACE-LY-308

A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study Of Bendamustine And Rituximab (BR) Alone Versus In Combination With Acalabrutinib (ACP 196) In Subjects With Previously Untreated Mantle Cell Lymphoma

DISEASE GROUP:
Lymphoma
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: